Renaissance Group LLC Buys 3,211 Shares of Jazz Pharmaceuticals PLC $JAZZ

Renaissance Group LLC boosted its stake in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 6.5% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 52,314 shares of the specialty pharmaceutical company’s stock after buying an additional 3,211 shares during the quarter. Renaissance Group LLC’s holdings in Jazz Pharmaceuticals were worth $8,893,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of the company. Janney Montgomery Scott LLC grew its stake in shares of Jazz Pharmaceuticals by 87.1% in the 4th quarter. Janney Montgomery Scott LLC now owns 23,878 shares of the specialty pharmaceutical company’s stock worth $4,059,000 after acquiring an additional 11,117 shares in the last quarter. Deutsche Bank AG raised its holdings in shares of Jazz Pharmaceuticals by 809.6% in the fourth quarter. Deutsche Bank AG now owns 140,286 shares of the specialty pharmaceutical company’s stock valued at $23,849,000 after purchasing an additional 124,864 shares during the last quarter. Allianz Asset Management GmbH lifted its position in shares of Jazz Pharmaceuticals by 68.2% during the fourth quarter. Allianz Asset Management GmbH now owns 598,832 shares of the specialty pharmaceutical company’s stock valued at $101,801,000 after purchasing an additional 242,892 shares in the last quarter. Focus Partners Advisor Solutions LLC bought a new position in shares of Jazz Pharmaceuticals during the fourth quarter valued at about $259,000. Finally, Cerity Partners LLC boosted its holdings in Jazz Pharmaceuticals by 5.4% during the fourth quarter. Cerity Partners LLC now owns 38,688 shares of the specialty pharmaceutical company’s stock worth $6,577,000 after purchasing an additional 1,968 shares during the last quarter. 89.14% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on JAZZ shares. Piper Sandler upped their price objective on shares of Jazz Pharmaceuticals from $232.00 to $301.00 and gave the stock an “overweight” rating in a research report on Friday, May 22nd. Leerink Partners lifted their target price on shares of Jazz Pharmaceuticals from $215.00 to $225.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 22nd. Royal Bank Of Canada boosted their target price on Jazz Pharmaceuticals from $195.00 to $258.00 and gave the stock an “outperform” rating in a research note on Wednesday, May 6th. Robert W. Baird set a $252.00 target price on Jazz Pharmaceuticals in a report on Wednesday, May 6th. Finally, UBS Group raised Jazz Pharmaceuticals from a “neutral” rating to a “buy” rating and increased their price target for the company from $188.00 to $307.00 in a research report on Tuesday, May 19th. Sixteen equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $246.06.

Insider Activity

In related news, Director Heather Ann Mcsharry sold 2,000 shares of the business’s stock in a transaction that occurred on Friday, May 22nd. The shares were sold at an average price of $241.00, for a total transaction of $482,000.00. Following the completion of the transaction, the director owned 18,449 shares of the company’s stock, valued at approximately $4,446,209. The trade was a 9.78% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Bruce C. Cozadd sold 6,000 shares of the company’s stock in a transaction that occurred on Wednesday, April 1st. The stock was sold at an average price of $190.50, for a total transaction of $1,143,000.00. Following the sale, the director directly owned 384,682 shares in the company, valued at $73,281,921. This trade represents a 1.54% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 10,741 shares of company stock worth $2,287,143 over the last ninety days. Company insiders own 4.30% of the company’s stock.

Jazz Pharmaceuticals Trading Up 0.2%

Shares of JAZZ opened at $229.63 on Thursday. Jazz Pharmaceuticals PLC has a fifty-two week low of $105.00 and a fifty-two week high of $243.32. The business has a 50-day moving average of $215.82 and a 200 day moving average of $188.13. The firm has a market cap of $14.43 billion, a P/E ratio of -11,475.76, a price-to-earnings-growth ratio of 0.22 and a beta of 0.32. The company has a debt-to-equity ratio of 0.95, a quick ratio of 1.85 and a current ratio of 2.04.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its earnings results on Tuesday, March 31st. The specialty pharmaceutical company reported $6.34 earnings per share for the quarter. The firm had revenue of $1.07 billion during the quarter. Jazz Pharmaceuticals had a net margin of 0.66% and a return on equity of 14.56%. As a group, research analysts forecast that Jazz Pharmaceuticals PLC will post 21.59 EPS for the current year.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.